Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 8/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | WNT1 | P04628 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 4/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2753411 | 0.83 | PDPK1 (0.46) | PDPK1BRD4PTPN11WNT1GSK3B | |
| SCHEMBL2752249 | 0.83 | PDPK1 (0.42) | PDPK1BRD4PTPN11WNT1GSK3B | |
| SCHEMBL2750994 | 0.82 | PDPK1 (0.54) | PDPK1BRD4PTPN11HTR6FGFR1 | |
| SCHEMBL2752474 | 0.82 | PDPK1 (0.44) | PDPK1BRD4PTPN11WNT1GSK3B | |
| SCHEMBL2753391 | 0.81 | PDPK1 (0.42) | PDPK1BRD4PTPN11WNT1GSK3B | |
| SCHEMBL2753387 | 0.81 | PDPK1 (0.42) | PDPK1BRD4PTPN11WNT1GSK3B | |
| SCHEMBL2752981 | 0.80 | PDPK1 (0.44) | PDPK1BRD4PTPN11WNT1GSK3B | |
| SCHEMBL2752522 | 0.80 | PDPK1 (0.44) | PDPK1BRD4PTPN11WNT1GSK3B | |
| SCHEMBL2750989 | 0.79 | PDPK1 (0.46) | PDPK1BRD4PTPN11HTR6 | |
| SCHEMBL2752309 | 0.79 | PDPK1 (0.46) | PDPK1BRD4PTPN11HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178552-B2 | 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178552-B2 | 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPK13, MAPKAPK5 | PDPK1 424/4885BRD4 780/4885PTPN11 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.